Weekly Digest – April 2025 Weekly Digest – April 2025 08 Apr 2025: DATROWAY approved in the EU for patients with previously treated metastatic HR positive, HER2 negative breast cancer DATROWAY has been approved in the EU for adults with […]
Weekly Digest – April 2025 Weekly Digest – April 2025 07 Apr 2025: ALX Oncology received FDA clearance for its investigational new drug (IND) application for ALX2004, a novel antibody-drug conjugate (ADC) targeting EGFR-expressing solid tumor ALX Oncology received FDA […]
Weekly Digest – April 2025 Weekly Digest – April 2025 10 Apr 2025: IDEAYA Biosciences announces Phase 1/2 expansion for IDE397 and Trodelvy combination in MTAP-deletion urothelial cancer IDEAYA Biosciences has begun a Phase 1/2 trial of a MAT2A inhibitor, […]
Weekly Digest – April 2025 Weekly Digest – April 2025 07 Apr 2025: Novelty Nobility, selected by JLABS Korea, hosted by Johnson & Johnson Novelty Nobility has joined JLABS Korea, Johnson & Johnson’s global incubator network, to accelerate its antibody […]
Weekly Digest – April 2025 Weekly Digest – April 2025 09 Apr 2025: OS Therapies completes acquisition of Advaxis Immunotherapies clinical, pre-clinical and IP assets from Ayala Pharmaceuticals OS Therapies (NYSE-A: OSTX) has completed the acquisition of listeria-based cancer immunotherapy […]
Weekly Digest – April 2025 Weekly Digest – April 2025 07 Apr 2025: Backing from BioNTech powers ADC specialist DualityBio toward $200M Hong Kong IPO DualityBio has officially launched its IPO in Hong Kong, aiming to raise up to $200 […]
